Press releasePRNewswire
IDEAYA Biosciences
IDYA · NASDAQ
$35.36+$1.55 (+4.58%)TodayMarket closed ·
Prev close $33.81
Latest news
- Press releasePRNewswire
IDEAYA Biosciences Announces the Promotion of Dr. Michael White to President, Research and Development
- Press releasePRNewswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- News
IDEAYA Biosciences Announced First Patient Has Been Dosed In The OptimUM-11 Phase 3 Registrational Trial Evaluating Darovasertib In Combination With Crizotinib For Patients With Primary Uveal Melanoma
- Press releasePRNewswire
IDEAYA Biosciences and Servier Announce First Patient Dosed in OptimUM-11 Global Phase 3 Registrational Trial of Darovasertib and Crizotinib as Adjuvant Therapy for Subjects with Uveal Melanoma
- Press releasePRNewswire
IDEAYA Biosciences Announces London Investor R&D Day and Participation in Upcoming September 2026 Investor Conferences
- Press releasePRNewswire
IDEAYA Biosciences Announces Successful FDA Type C Meeting for IDE849, DLL3 TOP1 ADC, on Phase 3 Registrational Trial Design for Potential Accelerated and Full Approval in Extensive Stage Small Cell Lung Cancer
- Press releasePRNewswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Press releasePRNewswire
IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer
- Press releasePRNewswire
IDEAYA Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Update
- Press releasePRNewswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Press releasePRNewswire
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers
- Press releasePRNewswire
IDEAYA Biosciences Announces ESMO 2026 Presentations for Darovasertib and IDE849 Clinical Programs
- Press releasePRNewswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Press releasePRNewswire
IDEAYA Biosciences Announces Yujiro S. Hata Elected Chairman of its Board of Directors
- Press releasePRNewswire
IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates a Phase 1/2 Clinical Combination Study in MTAP-Deleted Pancreatic and Lung Cancers
- Press releasePRNewswire
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
- NewsAvi Kapoor
Mission Produce Posts Downbeat Q2 Earnings, Joins Ideaya Biosciences, Perrigo And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- Press releasePRNewswire
IDEAYA Announces Pricing of $300 Million Offering of Common Stock and Pre-Funded Warrants
- Press releasePRNewswire
IDEAYA Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants
- Press releasePRNewswire
IDEAYA Biosciences Announces Clinical Collaboration with Roche in MTAP-Deleted RAS-Mutant Pancreatic Cancer
- Press releasePRNewswire
IDEAYA Biosciences and Servier Provide Complete Data from Phase 2/3 Registrational OptimUM-02 Trial of the Darovasertib Combination in First Line HLA*A2:01 Negative Metastatic Uveal Melanoma in a Late-Breaking Oral Presentation at ASCO
- Press releasePRNewswire
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Press releasePRNewswire
IDEAYA Biosciences Announces Participation at the 2026 Jefferies Global Healthcare Conference
- Press releasePRNewswire
B7-H3 Becomes The Hottest Antigen In Oncology, And One NK Engager Enters Clinic
- Press releaseGlobe Newswire
A Cancer Antigen Long Thought Untouchable Is Suddenly the Hottest Target in Oncology
- News
Earnings Scheduled For May 5, 2026
- Press releasePRNewswire
IDEAYA Biosciences Reports First Quarter 2026 Financial Results and Provides Business Update
- NewsVandana Singh
IDEAYA Eye Cancer Trial Data Beats Standard Therapy, Stock Soars
- News
Market-Moving News for April 13th
- News
Stock Market Today: Dow Futures Fall As Trump Announces Strait Of Hormuz Blockade—Goldman Sachs, Fastenal In Focus (UPDATED)
- News
Earnings Scheduled For February 17, 2026
- News
IDEAYA Biosciences Q4 Earnings Report: What Investors Need to Know
- News
IDEAYA Biosciences Q3 EPS $1.33 Beats $(0.47) Estimate, Sales $207.834M Beat $5.975M Estimate
- News
Market-Moving News for September 2nd
- News
12 Health Care Stocks Moving In Friday's After-Market Session
- NewsAvi Kapoor
Jim Cramer Says This Tobacco Stock Is 'Undervalued' But He's Not Recommending It
- NewsAvi Kapoor
Oracle To Rally Around 29%? Here Are 10 Top Analyst Forecasts For Tuesday
- NewsAvi Kapoor
Kura Sushi Posts Weak Q3 Results, Joins LegalZoom.com And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.